Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:United_States |
| gptkbp:ATCCode |
N07XA02
|
| gptkbp:CASNumber |
54-96-6
|
| gptkbp:chemicalFormula |
C5H7N3
|
| gptkbp:discoveredBy |
1970s
|
| https://www.w3.org/2000/01/rdf-schema#label |
3,4-diaminopyridine
|
| gptkbp:IUPACName |
pyridine-3,4-diamine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
potassium channel blocker
|
| gptkbp:meltingPoint |
218–220 °C
|
| gptkbp:molecularWeight |
109.13 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1201202
561 578 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea abdominal pain dizziness headache seizures insomnia paresthesia |
| gptkbp:synonym |
3,4-DAP
amifampridine |
| gptkbp:UNII |
9I51L432AG
|
| gptkbp:usedFor |
gptkb:Lambert-Eaton_myasthenic_syndrome
gptkb:congenital_myasthenic_syndromes gptkb:drug |
| gptkbp:bfsParent |
gptkb:Lambert-Eaton_Myasthenic_Syndrome
|
| gptkbp:bfsLayer |
6
|